Cargando…

Malignant hyperthermia: a review

Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine, and rarely, in humans, to stressors...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Henry, Pollock, Neil, Schiemann, Anja, Bulger, Terasa, Stowell, Kathryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524368/
https://www.ncbi.nlm.nih.gov/pubmed/26238698
http://dx.doi.org/10.1186/s13023-015-0310-1
_version_ 1782384180930281472
author Rosenberg, Henry
Pollock, Neil
Schiemann, Anja
Bulger, Terasa
Stowell, Kathryn
author_facet Rosenberg, Henry
Pollock, Neil
Schiemann, Anja
Bulger, Terasa
Stowell, Kathryn
author_sort Rosenberg, Henry
collection PubMed
description Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine, and rarely, in humans, to stressors such as vigorous exercise and heat. The incidence of MH reactions ranges from 1:10,000 to 1: 250,000 anesthetics. However, the prevalence of the genetic abnormalities may be as great as one in 400 individuals. MH affects humans, certain pig breeds, dogs and horses. The classic signs of MH include hyperthermia, tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, hyperkalaemia, muscle rigidity, and rhabdomyolysis, all related to a hypermetabolic response. The syndrome is likely to be fatal if untreated. An increase in end-tidal carbon dioxide despite increased minute ventilation provides an early diagnostic clue. In humans the syndrome is inherited in an autosomal dominant pattern, while in pigs it is autosomal recessive. Uncontrolled rise of myoplasmic calcium, which activates biochemical processes related to muscle activation leads to the pathophysiologic changes. In most cases, the syndrome is caused by a defect in the ryanodine receptor. Over 400 variants have been identified in the RYR1 gene located on chromosome 19q13.1, and at least 34 are causal for MH. Less than 1 % of variants have been found in CACNA1S but not all of these are causal. Diagnostic testing involves the in vitro contracture response of biopsied muscle to halothane, caffeine, and in some centres ryanodine and 4-chloro-m-cresol. Elucidation of the genetic changes has led to the introduction of DNA testing for susceptibility to MH. Dantrolene sodium is a specific antagonist and should be available wherever general anesthesia is administered. Increased understanding of the clinical manifestation and pathophysiology of the syndrome, has lead to the mortality decreasing from 80 % thirty years ago to <5 % in 2006.
format Online
Article
Text
id pubmed-4524368
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45243682015-08-05 Malignant hyperthermia: a review Rosenberg, Henry Pollock, Neil Schiemann, Anja Bulger, Terasa Stowell, Kathryn Orphanet J Rare Dis Review Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine, and rarely, in humans, to stressors such as vigorous exercise and heat. The incidence of MH reactions ranges from 1:10,000 to 1: 250,000 anesthetics. However, the prevalence of the genetic abnormalities may be as great as one in 400 individuals. MH affects humans, certain pig breeds, dogs and horses. The classic signs of MH include hyperthermia, tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, hyperkalaemia, muscle rigidity, and rhabdomyolysis, all related to a hypermetabolic response. The syndrome is likely to be fatal if untreated. An increase in end-tidal carbon dioxide despite increased minute ventilation provides an early diagnostic clue. In humans the syndrome is inherited in an autosomal dominant pattern, while in pigs it is autosomal recessive. Uncontrolled rise of myoplasmic calcium, which activates biochemical processes related to muscle activation leads to the pathophysiologic changes. In most cases, the syndrome is caused by a defect in the ryanodine receptor. Over 400 variants have been identified in the RYR1 gene located on chromosome 19q13.1, and at least 34 are causal for MH. Less than 1 % of variants have been found in CACNA1S but not all of these are causal. Diagnostic testing involves the in vitro contracture response of biopsied muscle to halothane, caffeine, and in some centres ryanodine and 4-chloro-m-cresol. Elucidation of the genetic changes has led to the introduction of DNA testing for susceptibility to MH. Dantrolene sodium is a specific antagonist and should be available wherever general anesthesia is administered. Increased understanding of the clinical manifestation and pathophysiology of the syndrome, has lead to the mortality decreasing from 80 % thirty years ago to <5 % in 2006. BioMed Central 2015-08-04 /pmc/articles/PMC4524368/ /pubmed/26238698 http://dx.doi.org/10.1186/s13023-015-0310-1 Text en © Rosenberg et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Rosenberg, Henry
Pollock, Neil
Schiemann, Anja
Bulger, Terasa
Stowell, Kathryn
Malignant hyperthermia: a review
title Malignant hyperthermia: a review
title_full Malignant hyperthermia: a review
title_fullStr Malignant hyperthermia: a review
title_full_unstemmed Malignant hyperthermia: a review
title_short Malignant hyperthermia: a review
title_sort malignant hyperthermia: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524368/
https://www.ncbi.nlm.nih.gov/pubmed/26238698
http://dx.doi.org/10.1186/s13023-015-0310-1
work_keys_str_mv AT rosenberghenry malignanthyperthermiaareview
AT pollockneil malignanthyperthermiaareview
AT schiemannanja malignanthyperthermiaareview
AT bulgerterasa malignanthyperthermiaareview
AT stowellkathryn malignanthyperthermiaareview